clearview healthcare partners linkedin harvard

#Clearview healthcare partners linkedin harvard professional#

In addition to her academic work, she co-founded Neumind, a digital health company working to provide accessible, world-class rehabilitation therapy to patients with brain injuries and neurological conditions. Her thesis investigated ways to enhance the pharmacokinetics and targeting of oncolytic (cancer-killing) viruses and her research was disseminated through peer-reviewed publications as well as a book chapter in Oncolytic Virotherapy. Prior to HBS, Claudia earned a PhD in biomedical engineering at Oxford University’s Centre of Drug Delivery and Devices, a multidisciplinary research environment that combined engineering of biology, chemistry, and medical devices with the aim of improving drug delivery. Adam said, “As a Kaplan Fellow, I hope to leverage my scientific background and business training to ultimately lower the barriers for bringing new medicine to patients in need.” Outside of the laboratory, Adam championed program development efforts exploring new applications of mRNA in oncology. He is proud to have contributed to one of the first COVID-19 vaccines in the world and Moderna’s first commercial product. There, he designed nanotechnologies for delivering mRNA medicine into the body. “With the next generation of startup companies being formed almost daily in the area comes a strong need for leaders that not only have a vigorous drive to alleviate human suffering, but also a uniquely tailored education and training to take on such a lofty task.”Īdam joins HBS after eight years at Moderna, where he worked in early-stage R&D. “Joining the third cohort of the MS/MBA: Biotechnology Program as a Kaplan Fellow is an opportunity that I do not take lightly,” Aaron says. His passion for developing innovative therapies to help patients suffering from serious diseases led him to work on mRNA vaccines at Novartis, gene therapies at bluebird bio, and most recently on gene-edited CAR-T programs at Beam Therapeutics. As a MS/MBA Biotechnology candidate, Bella is excited to, “bridge the gap between science and business by combining my technical background with the HBS curriculum, and ultimately launch novel medicines that benefit underserved patient populations.”Īaron joins HBS after nearly a decade as a scientist at multiple companies across Boston’s biotech sector. Outside the lab, she acted on her passion for diversity and inclusion to help spearhead relationships with historically black colleges and universities, aiming to increase representation of minorities in the biotechnology industry. Most recently, she transitioned to the cell therapy space to support the development of analytical methods for early-stage T cell therapies.

She started her career at Genentech where she learned the necessary steps to create and scale up end-to-end manufacturing processes for large molecule biotherapeutics. Prior to HBS, Bella spent five years working in the biotechnology industry as a benchtop scientist.

Gabriella (Bella) del Hierro (MS/MBA 2024) “It is exciting to welcome this new generation of leaders to Harvard’s thriving life science ecosystem.” Weatherhead III Professor of Business Administration and Howard Cox Health Care Initiative Faculty Chair. “This year’s Kaplan Fellows start their HBS journeys with diverse scientific backgrounds and will add tremendous value to the School as well as the business and biotech communities in Boston,” said Robert Huckman, Albert J. Kaplan Fellows express a strong commitment to continue a life science career after graduation, including applying to and completing the Blavatnik Fellowship in Life Science Entrepreneurship, which offers HBS alumni the opportunity to build a life science venture while developing their leadership talents. This year, many recipients are joint degree students in the MS/MBA Biotechnology: Life Sciences Program, which builds upon students’ existing biotech and life science knowledge and equips them with the latest business and scientific insights.

#Clearview healthcare partners linkedin harvard professional#

Past recipients of the award have demonstrated academic science achievements and professional leadership roles in the industry. The Kaplan Fellowship encourages students with credentials in the life science disciplines to attend HBS by awarding incoming MBA students up to $20,000.

Kaplan, who served as president and chief executive officer of the Federal Reserve Bank of Dallas, vice chairman of the Goldman Sachs Group, Inc., and was the Martin Marshall Professor of Practice at HBS.

Established in 2008, the fellowship was created by Robert S. Kaplan (MBA 1983) Life Sciences Fellowship. BOSTON-Harvard Business School (HBS) has announced this year’s recipients of the Robert S.